The effect of panel reactive antibodies and the donor specific crossmatch on graft survival after heart and heart-lung transplantation.
Data from 699 cardiac and 290 heart-lung transplants has been analysed to determine the importance of the lymphocytotoxic crossmatch result and panel reactive antibody (PRA) status on graft survival. Donor reactive crossmatching was performed for 636 cardiac transplants. One year actuarial survival for a negative crossmatch (n = 580) was 73% compared to 56% for the positive crossmatch recipients (n = 56) p = 0.0014. Where crossmatches were performed on separated T and B cells, the T cell directed crossmatch was found to be highly predictive of graft failure in 289 cardiac transplants. One year survival for a negative crossmatch was 73% (n = 258), for B cell positive crossmatch recipients 62% (n = 24), and for a positive T cell crossmatch 28% (n = 7) (p = 0.001). Patients' PRA status were grouped into those with negative, medium and high frequencies. There was a trend (not statistically significant) for patients with PRA above 50% to have poor graft survival. Patients with PRA above 50% were significantly more likely to have a positive lymphocytotoxic crossmatch against donor lymphocytes. Donor reactive crossmatching was performed for 283 heart-lung transplants. One year actuarial survival for a negative crossmatch was 61% (n = 251) and for a positive result was 50% (n = 32), p = 0.02.(ABSTRACT TRUNCATED AT 250 WORDS)
Smith
J D
JD
Department of Immunology, Harefield Hospital, Middlesex, UK.
Danskine
A J
AJ
Laylor
R M
RM
Rose
M L
ML
Yacoub
M H
MH
D000918:Antibody Specificity; D000961:Antilymphocyte Serum / Q000378:metabolism; D003602:Cytotoxicity, Immunologic; D006085:Graft Survival; D016027:Heart Transplantation / Q000276:immunology* / Q000401:mortality; D016041:Heart-Lung Transplantation / Q000276:immunology* / Q000401:mortality; D006650:Histocompatibility Testing; D006801:Humans; D015996:Survival Rate; D014019:Tissue Donors
D000961:Antilymphocyte Serum